In a major operation against spurious drugs, the Drugs Control Administration (DCA) Delhi has confiscated more than 1,400 spurious tubes of Thrombophob 20gm ointment from a whole seller in Bhagirath Place. The move was initiated following a complaint from Zydus Healthcare, the manufacturer of the original product, and regulatory authorities swooped down on a surprise raid.

Key Highlights

Fake Thrombophob Found at Delhi Market

• Zydus Healthcare informed the DCA about a fake product of Thrombophob being distributed at Delhi.

• Following the complaint, the DCA's intelligence cell traced the supply to Kyara Pharmaceuticals, owned by Tarun Kwatra.

Shock Raid Conducted at Bhagirath Place

• Joint raid was made by DCA officials and a Zydus vigilance group at Kyara Pharmaceuticals, Chandni Chowk.

• The officers recovered 1,408 tubes (Batch no. 1404138) that were labeled as produced by Zydus but were later authenticated as fakes through QR code verification.

QR Code Scan and Packaging Check Revealed Label vs. Zydus's Batch Data Discrepancies

• The QR code scan and packaging check indicated differences between the label and Zydus's batch data.

• The QR mechanism played a crucial role in authenticating the products as fakes.

Regulatory and Legal Action Taken

• The seized inventory of value ₹2.5 lakh was placed under custody according to Section 22(1)(c) of the Drugs and Cosmetics Act.

• Tarun Kwatra had confessed to keeping the infringing product in stock and selling it and was requested to reveal the source.

• Legal actions are being readied under the Drugs and Cosmetics Act.

All Evidence Digitally Documented

• The raid was video captured, and digital hash values were retained for legal evidence integrity.

• Tis Hazari Court has authorized the DCA to retain the stock in custody under regulation.

The big DCA Delhi seizure signals higher alert and technological uptake to counter fake medicines. The adoption of QR code scanning has shown up as an indispensable tool of swift on-location confirmation. Underway legal proceeding, the case emphasizes regulatory preparedness in guaranteeing patient security.